INCOG, which now employs just more than 400 people in Fishers, plans to have nearly 1,000 people working at its 21-acre campus by 2030.
Read More
Lewis sat down with IBJ to talk about his leadership style and the role of cycling in his life.
Read More
The Indianapolis-based drugmaker said the supercomputer will power an “AI factory” designed to accelerate drug discovery and development.
Read More
The new manufacturing sites are expected to create create 3,000 pharmaceutical jobs and nearly 10,000 construction positions during the buildout.
Read More
The companies developing new weight-loss medicines have a problem: People who don’t lose weight quickly figure out they were assigned to take a placebo and are bailing out of their clinical trials.
The late-stage results handily beat earlier trials of the company’s diabetes blockbuster Mounjaro, which racked up sales of $23 billion in 2025.
The Lilly Technology Center investment includes expanding existing capabilities and the establishment of new production lines.
Novo Nordisk is dismissing its patent infringement lawsuit against telehealth company Hims & Hers after an agreement that will see Novo Nordisk’s branded weight loss medicines sold through the Hims platform.
Tim Coleman has held positions within information technology at Lilly in research and development, sales and marketing, manufacturing, and human resources.
Generic Ozempic is set to emerge in major markets from India and Brazil to China and Canada this year, reshaping the sector in those countries.
While major drugmakers tussle for market supremacy, they are also taking on compound pharmacies that have not stopped selling obesity drugs despite the end of the shortage of such drugs.
Moderna President Stephen Hoge said that the company had previously engaged with the FDA on the trial design and that the agency had indicated it would be acceptable.
Shares in Indianapolis-based Eli Lilly and Co., a rival to Novo Nordisk in the weight-loss market, also fell after the announcement, dropping 7.8% Thursday.
The president first teased TrumpRx in September while announcing the first of his more than 15 deals with pharmaceutical companies, including Indianapolis-based Eli Lilly and Co., to lower drug prices.
Under the program, drugmakers are promised expedited reviews of one to two months for new medicines that support “national interests.”
The Indianapolis-based radiopharmaceutical company built a 150,000-square-foot production facility and plans to add up to jobs.
The new initiative expands on the massive artificial intelligence supercomputer collaboration the companies announced last fall.
People who stop taking GLP-1 drugs such as Ozempic, Wegovy and Zepbound for weight loss are projected to regain their shed pounds within about 1-½ years, a review of existing research has found.
The plant will focus on serving health care companies by developing and commercializing medical devices, drug delivery systems and combination products.
Novo Nordisk is aiming to avoid losing ground to its main rival, Eli Lilly, which is seeking regulatory approval for its own GLP-1 weight-loss pill.
Attorney General Todd Rokita said the lawsuit, filed last Wednesday in the Lake County Superior Court, is part of his office’s intensifying efforts to lower insulin prices and improve health care affordability.
Novo Nordisk’s Wegovy pills are expected to be available within weeks, while Indianapolis-based Eli Lilly and Co. waits for approval for its daily GLP-1 pill, orforglipron.
Eli Lilly and Co.’s career website this month listed 254 job openings in Indianapolis and another 90 in Lebanon, accounting for more than three-quarters of the 445 open positions the pharmaceutical giant listed across the United States.
Dr. Helen Bernie said on a Dec. 10 panel hosted by the U.S. Food and Drug Administration that serum testosterone “is one of the most powerful yet underutilized biomarkers for men’s health.”
